Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun;9(6):479-86.
doi: 10.1593/neo.07229.

Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts

Edmond Auzenne  1 , Sukhen C Ghosh, Mojgan Khodadadian, Belinda Rivera, David Farquhar, Roger E Price, Murali Ravoori, Vikas Kundra, Ralph S Freedman, Jim Klostergaard
Affiliations

Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts

Edmond Auzenne et al. Neoplasia. 2007 Jun.

Abstract

Numerous human tumor types, including ovarian cancer, display a significant expression of the CD44 family of cell surface proteoglycans. To develop tumor-targeted drugs, we have initially evaluated whether the CD44 ligand hyaluronic acid (HA) could serve as a backbone for paclitaxel (TXL) prodrugs. HA-TXL was prepared by modification of previous techniques. The in vitro cytotoxicity of HA-TXL against the CD44(+) human ovarian carcinoma cell lines SKOV-3ip and NMP-1 could be significantly blocked by preincubation with a molar excess of free HA. Female nude mice bearing intraperitoneal implants of NMP-1 cells were treated intraperitoneally with a single sub-maximum tolerated dose dose of HA-TXL or with multiple-dose regimens of paclitaxel (Taxol; Mead Johnson, Princeton, NJ) to determine the effects of these regimens on host survival and intraperitoneal tumor burden, with the latter being assessed by magnetic resonance imaging. NMP-1 xenografts were highly resistant to Taxol regimens, as host survival was only nominally improved compared to controls (T//C approximately 120), whereas single-dose HA-TXL treatment significantly improved survival in this model (T//C approximately 140; P = .004). In both NMP-1 and SKOV-3ip models, MR images of abdomens of HA-TXL-treated mice obtained shortly before controls required humane sacrifice revealed markedly reduced tumor burdens compared to control mice. This study is among the first to demonstrate that HA-based prodrugs administered locoregionally have antitumor activity in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T2-weighted coronal MR image of the abdomen of an NMP-1-implanted nude mouse (199 days following tumor inoculation) that was treated with a single intraperitoneal injection of 200 mg/kg HA-TXL 8 days post-tumor inoculation. No tumors were observed; compare to day 28 images of NMP-1 control mice in Figure 3A.
Figure 2
Figure 2
Kaplan-Meier survival plot of NMP-1- implanted mice treated intraperitoneally either with saline (controls), with 10 or 15 mg/kg Taxol on regimens of every 7 days x 3 beginning on day 7 post-tumor implantation, or with a single injection of 180 mg/kg HA-TXL (paclitaxel equivalents) on day 7. T/C values were 105 and 120 for the 10- and 15-mg/kg multiple-dose Taxol groups, respectively, and 140 for the single-dose HA-TXL group (P = .004 vs controls; Mantel-Cox).
Figure 3
Figure 3
Representative day 28 T2-weighted coronal abdominal MR images of NMP-1- implanted (A) control mice sham-treated with saline; arrows indicate examples of tumor masses throughout the abdomen; note the heavy tumor burden and areas of high signal intensity indicating ascites. (B) Mice treated with a multiple-dose intraperitoneal injection regimen of 10 mg/kg Taxol; arrows indicate examples of tumor masses throughout the abdomen; note evidence for ascites. (C) Mice treated with a multiple-dose intraperitoneal injection regimen of 15 mg/kg Taxol; note heavy tumor burden and ascites. (D) Mice treated with a single intraperitoneal injection of HA-TXL; note the comparatively modest tumor burden and few areas of high signal intensity indicating ascites. B = bladder.
Figure 4
Figure 4
Representative day 84 coronal T2-weighted MR images of the abdomens of SKOV-3ip-implanted mice from the control group (A) and the 180-mg/kg HA-TXL treatment group (B). Arrows indicate examples of intraperitoneal tumors; note the greater tumor burden in control versus treated mice. B = bladder. Comparison of tumor weights derived from MR images of mice bearing SKOV-3ip tumors (C; P < .03, n = 3; t-test).
See this image and copyright information in PMC

References

    1. Fields MM, Chevlen E. Screening for disease: making evidence-based choices. Clin J Oncol Nurs. 2006;10(1):73–76. Review. - PubMed
    1. Morrison J. Advances in the understanding and treatment of ovarian cancer. J Br Menopause Soc. 2005;11(2):66–71. Review. - PubMed
    1. Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschi S, Fedele L, La Vecchia C. Risk factors for different histological types of ovarian cancer. Int J Gynecol Cancer. 2004;14(3):431–436. - PubMed
    1. Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer. 2005;5:134. - PMC - PubMed
    1. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group, author. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol. 2006;24(4):579–586. - PubMed

Publication types

MeSH terms